TY - JOUR
T1 - Combined evaluation of plasma B-type natriuretic peptide and urinary liver-type fatty acid-binding protein/creatinine ratio is related to worsening renal function in patients undergoing elective percutaneous coronary intervention
AU - Yoshihara, Fumiki
AU - Hosoda, Hiroshi
AU - Doi, Takahito
AU - Yoshida, Morikatsu
AU - Kitamura, Kazuo
AU - Yamamoto, Haruko
AU - Asaumi, Yasuhide
AU - Ishibashi-Ueda, Hatsue
AU - Kishida, Masatsugu
AU - Arisato, Tetsuya
AU - Matsuo, Miki
AU - Miyazato, Mikiya
AU - Yasuda, Satoshi
N1 - Funding Information:
We thank Yoko Saito and Chie Nishiguchi for their excellent assistance. The present study was supported by Intramural Research Fund (29-3-2) for Cardiovascular Diseases of National Cerebral and Cardiovascular Center.
Publisher Copyright:
© 2021, Japanese Society of Nephrology.
PY - 2021/12
Y1 - 2021/12
N2 - Background: There are few reports on the significance for the combined evaluation of blood humoral factors and urinary biomarkers in terms of worsening renal function (WRF) after coronary angiography (CAG)/percutaneous coronary arterial intervention (PCI). Method and results: Urinary liver type-fatty acid-binding protein (L-FABP), neutrophil gelatinase associated lipocalin (NGAL), and adrenomedullin (AM) were measured less than 24 h before and 3 h, 6 h, 1 day, and 2 days after CAG/PCI. WRF was defined as a > 20% decrease in the estimated GFR. WRF occurred in seven of 100 patients and the increase in L-FABP/creatinine (Cr) at 1 day after CAG/PCI was significantly higher in the WRF group than in the non-WRF group. Plasma B-type natriuretic peptide (BNP) before CAG/PCI and L-FABP/Cr at 1 day after CAG/PCI were independent predictors for WRF. The areas under the receiver-operating characteristic curves were as follows: 0.760 for BNP before CAG/PCI, 0.731 for L-FABP/Cr at 1 day after CAG/PCI, and 0.892 for BNP and L-FABP/Cr. Urinary AM levels after PCI/CAG were negatively correlated only to serum potassium levels. Gene expressions of AM and AM-receptor were detectable in renal tubule epithelial cells. AM increased intracellular second messenger levels in a dose-dependent manner. Conclusions: Our results suggest that combined evaluation of plasma BNP and urinary L-FABP/Cr is useful as a predictor of renal dysfunction in CAG/PCI patients.
AB - Background: There are few reports on the significance for the combined evaluation of blood humoral factors and urinary biomarkers in terms of worsening renal function (WRF) after coronary angiography (CAG)/percutaneous coronary arterial intervention (PCI). Method and results: Urinary liver type-fatty acid-binding protein (L-FABP), neutrophil gelatinase associated lipocalin (NGAL), and adrenomedullin (AM) were measured less than 24 h before and 3 h, 6 h, 1 day, and 2 days after CAG/PCI. WRF was defined as a > 20% decrease in the estimated GFR. WRF occurred in seven of 100 patients and the increase in L-FABP/creatinine (Cr) at 1 day after CAG/PCI was significantly higher in the WRF group than in the non-WRF group. Plasma B-type natriuretic peptide (BNP) before CAG/PCI and L-FABP/Cr at 1 day after CAG/PCI were independent predictors for WRF. The areas under the receiver-operating characteristic curves were as follows: 0.760 for BNP before CAG/PCI, 0.731 for L-FABP/Cr at 1 day after CAG/PCI, and 0.892 for BNP and L-FABP/Cr. Urinary AM levels after PCI/CAG were negatively correlated only to serum potassium levels. Gene expressions of AM and AM-receptor were detectable in renal tubule epithelial cells. AM increased intracellular second messenger levels in a dose-dependent manner. Conclusions: Our results suggest that combined evaluation of plasma BNP and urinary L-FABP/Cr is useful as a predictor of renal dysfunction in CAG/PCI patients.
KW - Adrenomedullin
KW - B-type natriuretic peptide
KW - Liver type-fatty acid-binding protein
KW - Percutaneous coronary arterial intervention
KW - Worsening renal function
UR - http://www.scopus.com/inward/record.url?scp=85109941636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109941636&partnerID=8YFLogxK
U2 - 10.1007/s10157-021-02113-9
DO - 10.1007/s10157-021-02113-9
M3 - Article
C2 - 34255252
AN - SCOPUS:85109941636
VL - 25
SP - 1319
EP - 1328
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
SN - 1342-1751
IS - 12
ER -